Close Menu

hepatocellular carcinoma

Several genomic markers were associated with improved progression-free survival among patients treated with Tecentriq and Avastin versus Tecentriq alone. 

The vaccine, based on a patient's unique tumor variations, will be combined with cytokine immunomodulator IL-12 and a PD-1 checkpoint inhibitor.

CStone and Blueprint enrolled the first patient in a trial exploring the combination of the FGFR4 inhibitor fisogatinib and a PD-L1 inhibitor.